Abstract
Autoimmun kasalliklar qatoriga kiruvchi tizimli qizil yuguruk (SLE) va romatoid artrit (RA) surunkali yallig‘lanishli jarayonlar bilan kechib, bemorlarning hayot sifatini keskin pasaytiradi va og‘ir asoratlar bilan yakunlanadi. An’anaviy immunosupressiv terapiyalar ushbu kasalliklarda simptomlarni nazorat qilishda ma’lum darajada samara bersa-da, ko‘plab hollarda to‘liq remissiyaga erishilmaydi yoki nojo‘ya ta’sirlar sababli uzoq muddat qo‘llash mumkin emas. Yangi biologik terapiya vositalari esa kasallik patogenezidagi muhim sitokinlar, hujayra retseptorlari yoki yallig‘lanish yo‘llariga bevosita ta’sir ko‘rsatib, individuallashtirilgan va nishonli davolash imkonini yaratmoqda. Ushbu maqolada SLE va RA uchun ishlab chiqilgan va klinik amaliyotda qo‘llanila boshlagan biologik preparatlar, ularning samaradorligi va xavfsizlik profili ilmiy manbalar asosida yoritib beriladi.
References
1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. The Lancet. 2016;388(10055):2023–2038.
2. Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update on the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80(1):14–25.
3. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–731.
4. Furie R, Morand EF, Askanase AD, et al. Anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382:211–221.
5. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68(1):1–26.